After a decade plus of failed investment in the inhaled insulin, Exubera, Pfizer Inc. (NYSE:PFE) cut the losses via terminating its partnership with Nektar Therapeutics (NASDAQ:NKTR) on Oct. 18, 2007. Next year, Nektar gave up the hope for inhaled insulin by terminating all negotiations (with potential marketing partners) for the “the bong.”
